Meglumine iotroxate (Biliscopin)

Meglumine iotroxate (BiliscopinTM) is an iodinated, intravenous contrast agent that is preferentially excreted into the biliary tree and is used in CT intravenous cholangiography.

The typical dose is 100 mL Biliscopin (105 mg meglumine iotroxate/ml; 5.0 g iodine), which is administered via slow IV infusion (over 30-60 minutes) to optimise biliary concentration. 

Biliary opacification may be limited in cases of hyperbilirubinaemia (due to stasis or poor hepatocyte function), hyperproteinaemia, or in patients with excessively dilated ducts. Preferential renal excretion may occur in these patients 4. Bilirubin levels should be < 30 mmol/L to ensure optimal opacification, as opacification drops off when bilirubin levels are greater than 2-3 times normal 6

Contraindications

Contraindications include (but not limited to) 3

  • hyperbilirubinaemia: limited biliary opacification due to stasis or poor hepatocyte function
  • severe heart failure
  • iodinated-contrast hypersensitivity or allergy
  • thyrotoxicosis
  • severe hepatic or renal dysfunction
  • pregnancy: safety has not been established; demonstrated to be embryotoxic in rabbits 3

Complications

Adverse reactions are uncommon (~2%; range 0.8-3.4%) with no fatal reactions recorded and severe reactions (e.g. anaphylaxis) rare. Common reactions include pruritus, rash, hives and nausea 1,2

Share article

Article Information

rID: 32789
Section: Physics
Synonyms or Alternate Spellings:
  • Biliscopin
  • Iotroxate
  • Meglumine iotroxate

Support Radiopaedia and see fewer ads

Updating… Please wait.
Loadinganimation

Alert accept

Error Unable to process the form. Check for errors and try again.

Alert accept Thank you for updating your details.